Ozempic is not FDA-approved for weight loss. It is approved exclusively for adults with type 2 diabetes, and its label makes no mention of weight management as an indicated use. However, doctors can and do prescribe it off-label for weight loss, and roughly 30% of all Ozempic prescriptions in 2023 were for off-label purposes, nearly all related to obesity.
What Ozempic Is Actually Approved For
The FDA first approved Ozempic in 2017 for a single purpose: improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Since then, two additional indications have been added to its label, both still tied to type 2 diabetes. It is now also approved to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and established heart disease, and to slow kidney disease progression in adults with type 2 diabetes and chronic kidney disease.
That’s it. There is no weight loss indication anywhere on the Ozempic label.
Wegovy Is the Same Drug, Approved for Weight Loss
This is where the confusion comes from. Ozempic and Wegovy contain the exact same active ingredient, semaglutide, made by the same manufacturer. The difference is regulatory: Wegovy went through separate clinical trials specifically studying weight loss in people with and without diabetes, and it received its own FDA approval for weight management in adults and children 12 and older.
Wegovy also reaches a higher maximum dose. Both drugs are once-weekly injections, but Wegovy’s dosing schedule is designed to titrate up to a level optimized for weight reduction rather than blood sugar control. Wegovy is the only semaglutide product the FDA has approved for weight loss.
Why Doctors Prescribe Ozempic for Weight Loss Anyway
Off-label prescribing is legal and common across medicine. It means a doctor prescribes an FDA-approved drug for a purpose that isn’t on its official label. Because Ozempic contains the same molecule as Wegovy, many clinicians are comfortable prescribing it for weight management, particularly when Wegovy has been difficult to find due to supply constraints.
The scale of this practice is significant. Analysis of prescribing data shows off-label use of Ozempic grew from about 22% of prescriptions in 2018 to roughly 30% by 2023. Ozempic is used off-label more than any other drug in its class, with the increase driven largely by nurse practitioners and primary care physicians treating obesity-related conditions.
Insurance Rarely Covers Ozempic for Weight Loss
Because Ozempic lacks an FDA-approved weight loss indication, most insurance plans will not cover it when prescribed solely for obesity. If you have type 2 diabetes, your plan is far more likely to cover Ozempic, since that aligns with its approved use. If you don’t have diabetes and your doctor prescribes it off-label for weight, you may face a denial or need to pay out of pocket.
Even Medicare’s new GLP-1 Bridge program, set to begin providing weight-loss drug coverage in July 2026, does not list Ozempic among its eligible medications. That program will cover Wegovy and Zepbound for weight reduction, but not Ozempic. To qualify, beneficiaries will need a BMI of 35 or higher, or a BMI of 30 or above with certain conditions like uncontrolled high blood pressure or chronic kidney disease, or a BMI of 27 or above with conditions like prediabetes or a history of heart attack or stroke.
If your goal is covered weight-loss treatment, asking your doctor about Wegovy or another FDA-approved weight management medication will generally be a smoother path through the insurance process.
Side Effects Are the Same Regardless of Why You Take It
Whether prescribed for diabetes or used off-label for weight loss, Ozempic carries the same side effect profile. Nausea is the most common complaint and the most frequent reason people stop taking it. Other gastrointestinal effects include acid reflux, cramping, constipation, and delayed stomach emptying.
More serious but less common risks include pancreatitis and gallstones. Gallstones in particular tend to occur with rapid weight loss generally, not just with this medication. The side effects typically start during the dose escalation phase and improve over time as your body adjusts, though some people find they don’t tolerate the drug well enough to continue.
Supply Has Stabilized
Semaglutide spent an extended period on the FDA’s drug shortage list, which led to a boom in compounding pharmacies making custom versions of the drug. As of 2025, semaglutide no longer appears on the FDA shortage list, and the agency has noted that national supply is stabilizing. This matters because the shortage was one of the main reasons people ended up on Ozempic instead of Wegovy for weight loss: if Wegovy wasn’t available, Ozempic was sometimes the accessible alternative. With supply improving, the distinction between the two products becomes more practically relevant for new patients choosing between them.